Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Piroxicam
Drug ID BADD_D01784
Description A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Indications and Usage For treatment of osteoarthritis and rheumatoid arthritis.
Marketing Status approved; investigational
ATC Code M01AC01; M02AA07; S01BC06
DrugBank ID DB00554
KEGG ID D00127
MeSH ID D010894
PubChem ID 54676228
TTD Drug ID D00IBN
NDC Product Code 72789-211; 0093-0757; 71335-1999; 51927-1699; 70771-1429; 71335-2067; 72189-350; 22365-114; 59348-0014; 0093-0756; 29033-012; 42543-114; 71335-9622; 17337-0538; 38779-0302; 46438-0053; 49452-5476; 29300-255; 63629-9149; 0069-3220; 42291-674; 55700-697; 0069-3230; 62991-1113; 42291-677; 42571-177; 63629-9148; 71205-032; 72789-210; 59762-0145; 63629-9150; 53747-044; 60715-3270; 59762-0140; 64380-843; 70771-1430; 51927-0145; 60592-604; 63187-972; 64380-842; 71205-203; 46438-0639; 68981-041; 29033-013; 29300-256; 42543-115; 42571-176
UNII 13T4O6VMAM
Synonyms Piroxicam | CP-16171 | CP 16171 | CP16171 | Feldene
Chemical Information
Molecular Formula C15H13N3O4S
CAS Registry Number 36322-90-4
SMILES CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ecchymosis01.01.03.001; 23.06.01.001; 24.07.06.002---
Eczema23.03.04.006--
Eosinophilia01.02.04.001--
Epistaxis22.04.03.001; 24.07.01.005--
Eructation07.01.02.003--
Erythema23.03.06.0010.002127%-
Erythema multiforme10.01.03.015; 23.03.01.0030.001064%
Eye irritation06.04.05.003---
Eye swelling06.08.03.003---
Face oedema08.01.07.003; 10.01.05.002; 23.04.01.0040.001595%
Faeces discoloured07.01.03.0020.001595%-
Feeling abnormal08.01.09.014---
Flatulence07.01.04.002--
Fluid retention14.05.06.002; 20.01.02.003---
Flushing08.01.03.025; 23.06.05.003; 24.03.01.002--
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.0160.001064%
Gastric ulcer07.04.03.0020.002127%
Gastric ulcer haemorrhage07.04.03.005; 24.07.02.003---
Gastritis07.08.02.001--
Gastrointestinal disorder07.11.01.0010.002340%-
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.0090.002659%-
Gastrointestinal pain07.01.05.005--
Glomerulonephritis10.02.01.006; 20.05.01.001---
Glossitis07.14.01.001---
Haematemesis07.12.02.002; 24.07.02.0110.001064%-
Haematuria20.02.01.006; 21.10.01.018; 24.07.01.047--
Haemoglobin13.01.05.018---
Haemolytic anaemia01.06.03.002---
Hallucination19.10.04.003--
Headache17.14.01.001--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene